The Expert Angle

Medlior is a well-known and trusted industry leader.

Our team is dedicated to delivering high-quality research that provides a solid basis for informed decision-making. 

Medlior’s Expert Angle offers the inside track on new studies, industry hot topics, and what you need to know in the fast-paced world of clinical research, all from the point of view of the Medlior team of experts. From the latest topics and trends to the foundations of health and medical research, Medlior explores topics relevant to clients and the world. 

Medlior – Continuing Our Growth For The Future

Medlior – Continuing Our Growth For The Future

Since 2008, when Founder Tara Cowling started Medlior Health Outcomes Research, we have grown by leaps and bounds. The Medlior team now has 15 full-time staff with another 40 regular contractors - all of whom hold advanced degrees - that allow us to offer a range of research services ...
HTAi 2019: Best Practices for Leveraging Artificial Intelligence in the Systematic Review Process

HTAi 2019: Best Practices for Leveraging Artificial Intelligence in the Systematic Review Process

During the 2019 annual HTAi meeting in Cologne, Germany, Medlior’s Kelly Larkin-Kaiser along with Peter O’Blenis and Jennifer Tetzlaff from Evidence Partners hosted a workshop titled: “Best Practices for Leveraging Artificial Intelligence in the Systematic Review Process” The workshop ...
Medlior awarded inaugural Women’s Entrepreneurship Fund from Government of Canada

Medlior awarded inaugural Women’s Entrepreneurship Fund from Government of Canada

Fund awarded to Canadian women entrepreneurs to provide market opportunities and support growth Calgary, Alberta (May 20, 2019) - Calgary based company, Medlior Health Outcomes Research Ltd., has been awarded the Women Entrepreneurship Fund by the Government of Canada. This unique fund ...
Gene Therapy and the Treatment of Haemophilia

Gene Therapy and the Treatment of Haemophilia

Gene therapy is a growing area of interest for the treatment of several diseases. These therapies are intended to offer a one-time treatment to modify a person’s genes through a variety of mechanisms in order to treat or cure a disease.  These mechanisms include: i) replacing the gene with a ...
Cholesterol-lowering drugs are under-prescribed for prevention of atherosclerotic cardiovascular disease

Cholesterol-lowering drugs are under-prescribed for prevention of atherosclerotic cardiovascular disease

  Cholesterol-lowering drugs are under-prescribed for prevention of atherosclerotic cardiovascular disease In a large retrospective study, investigators identify a significant treatment gap in managing patients with and at risk for clinical atherosclerotic cardiovascular disease, ...
ASCO 2019: IdeNtiFying Outcomes in Real-World Multiple Myeloma

ASCO 2019: IdeNtiFying Outcomes in Real-World Multiple Myeloma

Early mortality following the diagnosis of multiple myeloma from 2011 to 2016 in Alberta, Canada: Initial results from the population-based Identifying Outcomes in Real-World Multiple Myeloma (INFORMM) study In addition to the treatment landscape results presented at the 24th Congress of the
EHA 2019: IdeNtiFying Outcomes in Real-World Multiple Myeloma

EHA 2019: IdeNtiFying Outcomes in Real-World Multiple Myeloma

Multiple Myeloma Treatment Landscape from 2011 to 2016 in Alberta, Canada: Results From the Population-Based “Identifying Outcomes in Real-World Multiple Myeloma” (INFORMM) Study Building on the Methodology Poster presented at the 2019 CADTH Symposium, we will be presenting results on ...
Low-density Lipoprotein Cholesterol Management in Patients with Atherosclerotic Cardiovascular Diseases and Pre-Existing Diabetes

Low-density Lipoprotein Cholesterol Management in Patients with Atherosclerotic Cardiovascular Diseases and Pre-Existing Diabetes

Building on previously published results,1,2 we are presenting results on the low-density lipoprotein (LDL-C) management in a subgroup of patients with atherosclerotic cardiovascular diseases (ASCVD) and pre-existing diabetes from Alberta, Canada at the American Diabetes Association (ADA) 79th ...
The Role of Modeling in RWE

The Role of Modeling in RWE

The use of Real-World Data (RWD) in health economics research has been significantly increasing over the past decade. The growing availability of longitudinal observational health data together with big-data analytics has now enabled us to go beyond the efficacy of interventions and inform ...
Medlior awarded inaugural funding through Government of Canada’s Women Entrepreneurship Fund

Medlior awarded inaugural funding through Government of Canada’s Women Entrepreneurship Fund

Fund assists Canadian women entrepreneurs to grow their businesses and expand market opportunities  Medlior Health Outcomes Research Ltd. has been selected as a recipient of the Women Entrepreneurship Fund by the Government of Canada. This unique fund provides support to women to grow their ...
Canadian firm Medlior impacts global health research with launch of Real World Radar directory

Canadian firm Medlior impacts global health research with launch of Real World Radar directory

Canadian firm Medlior impacts global health research with launch of Real World Radar directory Comprehensive listing of Real World Datasets is first of its kind Calgary, Alberta - (May 3, 2019) Medlior Health Outcomes Research Ltd. is positively impacting global health outcomes research ...
CADTH 2019: IdeNtiFying Outcomes in Real-World Multiple Myeloma

CADTH 2019: IdeNtiFying Outcomes in Real-World Multiple Myeloma

IdeNtiFying Outcomes in Real-World Multiple Myeloma (INFORMM): Insights in Methodology for Using Administrative Health Data in Alberta An ongoing study of newly-diagnosed multiple myeloma (MM) is the first of its kind in Canada to explore real-world treatments, survival and health system ...